Brandon Capital Partners

A fund management business focused on investments in life science ventures
Brandon Capital Partners

Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.

E89 - Stephen Thompson, Brandon Capital Partners



QUE Oncology



Taken on 2017-12
Blog Posts
21st December, 2020
With health policy top of the political agenda, now’s the time to supercharge Australia’s biotech sector says new MRCF Board member

Erica Kneipp, Head of Health and Medical Research Strategy at ANU, who was instrumental in establish...

21st December, 2020
Erica Kneipp tapped for $700m biotech fund

Former assistant secretary of the Department of Health Erica Kneipp has been tapped to join the boar...

18th December, 2020
Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals

Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journ...

21st November, 2020
Nasal spray which could fight Covid and other respiratory infections gets funding

A nasal spray with the potential to fight Covid-19 and other respiratory viral infections will be te...

17th November, 2020
New investments for drug research

Brandon Capital, Sofinnova Partners invest $8.2 m in new UK start-up seeking novel cancer blocker. T...

16th November, 2020
Myricx Pharma Launches with £4.5M (AUD$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer

Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of wo...

5th November, 2020
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period

PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, today annou...

1st November, 2020
Aravax appoints Financial Executive Thomas Ulmer to Board of Directors

Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effe...

28th October, 2020
OncoRes Medical wins IGNITE Madness 2020

Perth-based medtech company, OncoRes Medical, has taken out the IGNITE Madness pitch competition in ...

25th October, 2020
Eyeing pandemic’s silver lining for drug trials

The coronavirus pandemic has battered the smooth running of clinical trials for new drugs worldwide,...